22 related articles for article (PubMed ID: 38569519)
1. Integrated analysis of single-cell and bulk RNA sequencing data reveals a myeloid cell-related regulon predicting neoadjuvant immunotherapy response across cancers.
Liu H; Sima X; Xiao B; Gulizeba H; Zhao S; Zhou T; Huang Y
J Transl Med; 2024 May; 22(1):486. PubMed ID: 38773508
[TBL] [Abstract][Full Text] [Related]
2. Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma.
Liu H; Gao J; Feng M; Cheng J; Tang Y; Cao Q; Zhao Z; Meng Z; Zhang J; Zhang G; Zhang C; Zhao M; Yan Y; Wang Y; Xue R; Zhang N; Li H
Cancer Cell; 2024 May; ():. PubMed ID: 38759655
[TBL] [Abstract][Full Text] [Related]
3. Integrated analysis of single-cell and bulk RNA sequencing data reveals a pan-cancer stemness signature predicting immunotherapy response.
Zhang Z; Wang ZX; Chen YX; Wu HX; Yin L; Zhao Q; Luo HY; Zeng ZL; Qiu MZ; Xu RH
Genome Med; 2022 Apr; 14(1):45. PubMed ID: 35488273
[TBL] [Abstract][Full Text] [Related]
4. Pan-cancer analysis implicates novel insights of lactate metabolism into immunotherapy response prediction and survival prognostication.
Chen D; Liu P; Lu X; Li J; Qi D; Zang L; Lin J; Liu Y; Zhai S; Fu D; Weng Y; Li H; Shen B
J Exp Clin Cancer Res; 2024 Apr; 43(1):125. PubMed ID: 38664705
[TBL] [Abstract][Full Text] [Related]
5. Pan-cancer evaluation of regulated cell death to predict overall survival and immune checkpoint inhibitor response.
Zhang W; Zhu Y; Liu H; Zhang Y; Liu H; Adegboro AA; Dang R; Dai L; Wanggou S; Li X
NPJ Precis Oncol; 2024 Mar; 8(1):77. PubMed ID: 38538696
[TBL] [Abstract][Full Text] [Related]
6. Tumor-Infiltrating PD-1
Yang Z; Deng Y; Cheng J; Wei S; Luo H; Liu L
Front Oncol; 2021; 11():695006. PubMed ID: 34604032
[TBL] [Abstract][Full Text] [Related]
7. Divergent tumor and immune cell reprogramming underlying immunotherapy response and immune-related adverse events in lung squamous cell carcinoma.
Chen M; Ma P; Zhang Y; Wang D; Yu Z; Fu Y; Zhao X; Wang M; Zhuang G; Jing Y
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857527
[TBL] [Abstract][Full Text] [Related]
8. Modulating tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors: A TAM-pting approach.
Chamseddine AN; Assi T; Mir O; Chouaib S
Pharmacol Ther; 2022 Mar; 231():107986. PubMed ID: 34481812
[TBL] [Abstract][Full Text] [Related]
9. Improving Immunotherapy Efficacy in Soft-Tissue Sarcomas: A Biomarker Driven and Histotype Tailored Review.
Roulleaux Dugage M; Nassif EF; Italiano A; Bahleda R
Front Immunol; 2021; 12():775761. PubMed ID: 34925348
[TBL] [Abstract][Full Text] [Related]
10. Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy.
Ding S; Chen X; Shen K
Cancer Commun (Lond); 2020 Aug; 40(8):329-344. PubMed ID: 32654419
[TBL] [Abstract][Full Text] [Related]
11. Pan-Cancer Single-Cell and Spatial-Resolved Profiling Reveals the Immunosuppressive Role of APOE+ Macrophages in Immune Checkpoint Inhibitor Therapy.
Liu C; Xie J; Lin B; Tian W; Wu Y; Xin S; Hong L; Li X; Liu L; Jin Y; Tang H; Deng X; Zou Y; Zheng S; Fang W; Cheng J; Dai X; Bao X; Zhao P
Adv Sci (Weinh); 2024 Apr; ():e2401061. PubMed ID: 38569519
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
